Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Down - Time to Sell?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report)'s stock price gapped down prior to trading on Thursday . The stock had previously closed at $5.04, but opened at $4.28. Ironwood Pharmaceuticals shares last traded at $4.65, with a volume of 175,590 shares changing hands.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Wells Fargo & Company reduced their price target on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an "overweight" rating on the stock in a research report on Friday, August 9th. StockNews.com upgraded Ironwood Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Monday. Leerink Partners assumed coverage on Ironwood Pharmaceuticals in a research report on Monday, September 9th. They set a "market perform" rating and a $5.00 price objective for the company. Craig Hallum decreased their target price on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a "buy" rating on the stock in a research report on Friday, August 9th. Finally, Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a "hold" rating in a report on Monday, September 9th. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Ironwood Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $12.17.

Ironwood Pharmaceuticals Stock Performance

The business's fifty day moving average is $4.33 and its 200-day moving average is $5.64. The firm has a market cap of $744.39 million, a P/E ratio of 115.25 and a beta of 0.47.

Insider Buying and Selling

In other news, insider Minardo John sold 9,910 shares of the firm's stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the transaction, the insider now directly owns 284,661 shares in the company, valued at $1,215,502.47. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 12.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several large investors have recently modified their holdings of IRWD. Royce & Associates LP boosted its position in shares of Ironwood Pharmaceuticals by 10.8% during the 3rd quarter. Royce & Associates LP now owns 662,934 shares of the biotechnology company's stock valued at $2,731,000 after purchasing an additional 64,353 shares in the last quarter. KBC Group NV increased its stake in shares of Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 3,198 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Ironwood Pharmaceuticals by 194.9% during the third quarter. GSA Capital Partners LLP now owns 351,193 shares of the biotechnology company's stock worth $1,447,000 after acquiring an additional 232,087 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its position in shares of Ironwood Pharmaceuticals by 1,293.6% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 380,960 shares of the biotechnology company's stock worth $1,570,000 after purchasing an additional 353,624 shares in the last quarter. Finally, Harbor Capital Advisors Inc. boosted its holdings in Ironwood Pharmaceuticals by 50.1% in the third quarter. Harbor Capital Advisors Inc. now owns 168,071 shares of the biotechnology company's stock worth $692,000 after acquiring an additional 56,097 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.